nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—KIT—kidney cancer	0.0864	0.283	CbGaD
Imatinib—CA9—kidney cancer	0.083	0.272	CbGaD
Imatinib—CA2—kidney cancer	0.0747	0.245	CbGaD
Imatinib—PIP4K2C—Pazopanib—kidney cancer	0.0491	0.106	CbGbCtD
Imatinib—PTGS1—kidney cancer	0.041	0.134	CbGaD
Imatinib—PIP4K2C—Erlotinib—kidney cancer	0.0351	0.0753	CbGbCtD
Imatinib—KIT—Pazopanib—kidney cancer	0.0224	0.0482	CbGbCtD
Imatinib—CSF1R—Pazopanib—kidney cancer	0.0224	0.0482	CbGbCtD
Imatinib—PDGFRA—Pazopanib—kidney cancer	0.0224	0.0482	CbGbCtD
Imatinib—PDGFRB—Pazopanib—kidney cancer	0.0204	0.0438	CbGbCtD
Imatinib—LCK—Pazopanib—kidney cancer	0.0204	0.0438	CbGbCtD
Imatinib—ABCB1—kidney cancer	0.0199	0.0653	CbGaD
Imatinib—HIPK4—Erlotinib—kidney cancer	0.0178	0.0382	CbGbCtD
Imatinib—ABL2—Erlotinib—kidney cancer	0.016	0.0344	CbGbCtD
Imatinib—NTRK1—Sunitinib—kidney cancer	0.0154	0.033	CbGbCtD
Imatinib—HIPK4—Sorafenib—kidney cancer	0.0145	0.0311	CbGbCtD
Imatinib—KIT—Sorafenib—kidney cancer	0.013	0.0279	CbGbCtD
Imatinib—CSF1R—Sorafenib—kidney cancer	0.013	0.0279	CbGbCtD
Imatinib—PDGFRA—Sorafenib—kidney cancer	0.013	0.0279	CbGbCtD
Imatinib—PDGFRB—Sorafenib—kidney cancer	0.0118	0.0254	CbGbCtD
Imatinib—HIPK4—Sunitinib—kidney cancer	0.0117	0.0252	CbGbCtD
Imatinib—ABL1—Erlotinib—kidney cancer	0.0116	0.0248	CbGbCtD
Imatinib—PDGFRA—Sunitinib—kidney cancer	0.0105	0.0226	CbGbCtD
Imatinib—KIT—Sunitinib—kidney cancer	0.0105	0.0226	CbGbCtD
Imatinib—CSF1R—Sunitinib—kidney cancer	0.0105	0.0226	CbGbCtD
Imatinib—PDGFRB—Sunitinib—kidney cancer	0.00959	0.0206	CbGbCtD
Imatinib—CYP3A7—Temsirolimus—kidney cancer	0.00521	0.0112	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.00521	0.0112	CbGbCtD
Imatinib—ORM1—Erlotinib—kidney cancer	0.00433	0.0093	CbGbCtD
Imatinib—CYP3A5—Temsirolimus—kidney cancer	0.0039	0.00839	CbGbCtD
Imatinib—ABCG2—Pazopanib—kidney cancer	0.0037	0.00795	CbGbCtD
Imatinib—ABCG2—Dactinomycin—kidney cancer	0.00339	0.00727	CbGbCtD
Imatinib—SLC22A2—Vinblastine—kidney cancer	0.00287	0.00617	CbGbCtD
Imatinib—ABCG2—Erlotinib—kidney cancer	0.00264	0.00567	CbGbCtD
Imatinib—ABCB1—Temsirolimus—kidney cancer	0.00254	0.00546	CbGbCtD
Imatinib—ABCG2—Paclitaxel—kidney cancer	0.00242	0.00519	CbGbCtD
Imatinib—CYP2D6—Temsirolimus—kidney cancer	0.00239	0.00514	CbGbCtD
Imatinib—CYP3A4—Everolimus—kidney cancer	0.00225	0.00484	CbGbCtD
Imatinib—CA2—collecting duct of renal tubule—kidney cancer	0.00221	0.0662	CbGeAlD
Imatinib—ABCG2—Sorafenib—kidney cancer	0.00215	0.00461	CbGbCtD
Imatinib—ABCG2—Vincristine—kidney cancer	0.00209	0.00448	CbGbCtD
Imatinib—SLC22A2—nephron—kidney cancer	0.00197	0.0591	CbGeAlD
Imatinib—ALB—Erlotinib—kidney cancer	0.00182	0.00391	CbGbCtD
Imatinib—CYP3A7—Paclitaxel—kidney cancer	0.00179	0.00384	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.00179	0.00384	CbGbCtD
Imatinib—ABCG2—Sunitinib—kidney cancer	0.00174	0.00374	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.00159	0.00341	CbGbCtD
Imatinib—CYP3A7—Sorafenib—kidney cancer	0.00159	0.00341	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.00154	0.00331	CbGbCtD
Imatinib—CYP3A7—Vincristine—kidney cancer	0.00154	0.00331	CbGbCtD
Imatinib—CYP1A2—Pazopanib—kidney cancer	0.00153	0.00328	CbGbCtD
Imatinib—CYP3A4—Temsirolimus—kidney cancer	0.00152	0.00327	CbGbCtD
Imatinib—CYP3A5—Erlotinib—kidney cancer	0.00146	0.00314	CbGbCtD
Imatinib—CYP2C9—Capecitabine—kidney cancer	0.00143	0.00308	CbGbCtD
Imatinib—CYP3A5—Paclitaxel—kidney cancer	0.00134	0.00288	CbGbCtD
Imatinib—ABCB1—Pazopanib—kidney cancer	0.00134	0.00287	CbGbCtD
Imatinib—ABCG2—Doxorubicin—kidney cancer	0.0013	0.0028	CbGbCtD
Imatinib—CYP3A7—Sunitinib—kidney cancer	0.00129	0.00276	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.00129	0.00276	CbGbCtD
Imatinib—CYP2D6—Pazopanib—kidney cancer	0.00126	0.0027	CbGbCtD
Imatinib—ABCB1—Dactinomycin—kidney cancer	0.00122	0.00262	CbGbCtD
Imatinib—CYP3A5—Sorafenib—kidney cancer	0.00119	0.00256	CbGbCtD
Imatinib—CYP3A5—Vincristine—kidney cancer	0.00116	0.00248	CbGbCtD
Imatinib—CYP1A2—Erlotinib—kidney cancer	0.00109	0.00234	CbGbCtD
Imatinib—DDR1—nephron tubule—kidney cancer	0.000992	0.0297	CbGeAlD
Imatinib—ABCB1—Gemcitabine—kidney cancer	0.000965	0.00207	CbGbCtD
Imatinib—CYP3A5—Sunitinib—kidney cancer	0.000964	0.00207	CbGbCtD
Imatinib—CYP2C19—Sorafenib—kidney cancer	0.00096	0.00206	CbGbCtD
Imatinib—ABCB1—Erlotinib—kidney cancer	0.000953	0.00205	CbGbCtD
Imatinib—ABCA3—cortex of kidney—kidney cancer	0.00092	0.0275	CbGeAlD
Imatinib—CYP2C9—Paclitaxel—kidney cancer	0.000899	0.00193	CbGbCtD
Imatinib—CYP2D6—Erlotinib—kidney cancer	0.000898	0.00193	CbGbCtD
Imatinib—HIPK4—gonad—kidney cancer	0.000886	0.0265	CbGeAlD
Imatinib—CYP1A2—Sorafenib—kidney cancer	0.000886	0.0019	CbGbCtD
Imatinib—ABCB1—Paclitaxel—kidney cancer	0.000872	0.00187	CbGbCtD
Imatinib—CYP2C19—urine—kidney cancer	0.000862	0.0258	CbGeAlD
Imatinib—DDR1—cortex of kidney—kidney cancer	0.000849	0.0254	CbGeAlD
Imatinib—DDR1—cardiac atrium—kidney cancer	0.000808	0.0242	CbGeAlD
Imatinib—CYP3A4—Pazopanib—kidney cancer	0.0008	0.00172	CbGbCtD
Imatinib—CYP2C9—Sorafenib—kidney cancer	0.000798	0.00171	CbGbCtD
Imatinib—ABCB1—Sorafenib—kidney cancer	0.000775	0.00166	CbGbCtD
Imatinib—ABCB1—Vinblastine—kidney cancer	0.000765	0.00164	CbGbCtD
Imatinib—ABCB1—Vincristine—kidney cancer	0.000752	0.00162	CbGbCtD
Imatinib—CYP2D6—Sorafenib—kidney cancer	0.00073	0.00157	CbGbCtD
Imatinib—CYP2D6—Vinblastine—kidney cancer	0.000721	0.00155	CbGbCtD
Imatinib—CYP1A2—urine—kidney cancer	0.000704	0.0211	CbGeAlD
Imatinib—CYP2C9—urine—kidney cancer	0.000668	0.02	CbGeAlD
Imatinib—ABCB1—Sunitinib—kidney cancer	0.000628	0.00135	CbGbCtD
Imatinib—PIP4K2C—nephron tubule—kidney cancer	0.000612	0.0183	CbGeAlD
Imatinib—CA7—renal system—kidney cancer	0.000579	0.0173	CbGeAlD
Imatinib—CYP3A4—Erlotinib—kidney cancer	0.000571	0.00123	CbGbCtD
Imatinib—CA7—kidney—kidney cancer	0.00056	0.0168	CbGeAlD
Imatinib—PIP4K2C—cortex of kidney—kidney cancer	0.000524	0.0157	CbGeAlD
Imatinib—CYP3A4—Paclitaxel—kidney cancer	0.000522	0.00112	CbGbCtD
Imatinib—CYP3A4—urine—kidney cancer	0.00051	0.0153	CbGeAlD
Imatinib—CYP2D6—urine—kidney cancer	0.000501	0.015	CbGeAlD
Imatinib—PIP4K2C—gonad—kidney cancer	0.000499	0.0149	CbGeAlD
Imatinib—PIP4K2C—cardiac atrium—kidney cancer	0.000499	0.0149	CbGeAlD
Imatinib—Ponatinib—KDR—kidney cancer	0.000498	0.194	CrCbGaD
Imatinib—CA3—cardiac atrium—kidney cancer	0.000476	0.0142	CbGeAlD
Imatinib—Ponatinib—KIT—kidney cancer	0.00047	0.183	CrCbGaD
Imatinib—ABCB1—Doxorubicin—kidney cancer	0.00047	0.00101	CbGbCtD
Imatinib—CYP3A4—Sorafenib—kidney cancer	0.000464	0.000997	CbGbCtD
Imatinib—CYP3A4—Vinblastine—kidney cancer	0.000458	0.000984	CbGbCtD
Imatinib—CYP3A4—Vincristine—kidney cancer	0.000451	0.000968	CbGbCtD
Imatinib—NQO2—nephron tubule—kidney cancer	0.00045	0.0135	CbGeAlD
Imatinib—CYP2D6—Doxorubicin—kidney cancer	0.000443	0.000951	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.000442	0.0132	CbGeAlD
Imatinib—Nilotinib—BRAF—kidney cancer	0.000432	0.168	CrCbGaD
Imatinib—CA14—cardiac atrium—kidney cancer	0.000432	0.0129	CbGeAlD
Imatinib—SLC22A2—nephron tubule—kidney cancer	0.000426	0.0128	CbGeAlD
Imatinib—NQO2—renal system—kidney cancer	0.000409	0.0122	CbGeAlD
Imatinib—PDGFRA—renal system—kidney cancer	0.000408	0.0122	CbGeAlD
Imatinib—NQO2—kidney—kidney cancer	0.000395	0.0118	CbGeAlD
Imatinib—SLC22A2—renal system—kidney cancer	0.000387	0.0116	CbGeAlD
Imatinib—NQO2—cortex of kidney—kidney cancer	0.000385	0.0115	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.000378	0.0113	CbGeAlD
Imatinib—CA12—renal system—kidney cancer	0.000376	0.0113	CbGeAlD
Imatinib—CYP3A4—Sunitinib—kidney cancer	0.000376	0.000808	CbGbCtD
Imatinib—SLC22A2—kidney—kidney cancer	0.000374	0.0112	CbGeAlD
Imatinib—NQO2—cardiac atrium—kidney cancer	0.000366	0.011	CbGeAlD
Imatinib—PDGFRA—gonad—kidney cancer	0.000366	0.0109	CbGeAlD
Imatinib—SLC22A2—cortex of kidney—kidney cancer	0.000365	0.0109	CbGeAlD
Imatinib—CA12—kidney—kidney cancer	0.000364	0.0109	CbGeAlD
Imatinib—SLC47A1—nephron tubule—kidney cancer	0.000361	0.0108	CbGeAlD
Imatinib—KIT—nephron tubule—kidney cancer	0.000359	0.0107	CbGeAlD
Imatinib—Nilotinib—KIT—kidney cancer	0.000347	0.135	CrCbGaD
Imatinib—Nilotinib—CA9—kidney cancer	0.000333	0.13	CrCbGaD
Imatinib—SLC47A1—renal system—kidney cancer	0.000328	0.00982	CbGeAlD
Imatinib—KIT—renal system—kidney cancer	0.000326	0.00976	CbGeAlD
Imatinib—CSF1R—gonad—kidney cancer	0.000322	0.00964	CbGeAlD
Imatinib—CSF1R—cardiac atrium—kidney cancer	0.000322	0.00963	CbGeAlD
Imatinib—PDGFRB—renal system—kidney cancer	0.000318	0.00953	CbGeAlD
Imatinib—SLC47A1—kidney—kidney cancer	0.000317	0.00949	CbGeAlD
Imatinib—KIT—kidney—kidney cancer	0.000315	0.00943	CbGeAlD
Imatinib—ABL1—nephron tubule—kidney cancer	0.000312	0.00935	CbGeAlD
Imatinib—SLC47A1—cortex of kidney—kidney cancer	0.000309	0.00924	CbGeAlD
Imatinib—PDGFRB—kidney—kidney cancer	0.000308	0.00921	CbGeAlD
Imatinib—KIT—cortex of kidney—kidney cancer	0.000307	0.00919	CbGeAlD
Imatinib—PDGFRB—cortex of kidney—kidney cancer	0.0003	0.00897	CbGeAlD
Imatinib—Nilotinib—CA2—kidney cancer	0.0003	0.117	CrCbGaD
Imatinib—CA1—renal system—kidney cancer	0.000298	0.00893	CbGeAlD
Imatinib—ABL1—Epirubicin—Doxorubicin—kidney cancer	0.000295	0.333	CbGdCrCtD
Imatinib—ABL1—Daunorubicin—Doxorubicin—kidney cancer	0.000295	0.333	CbGdCrCtD
Imatinib—ABL1—Idarubicin—Doxorubicin—kidney cancer	0.000295	0.333	CbGdCrCtD
Imatinib—SLC47A1—gonad—kidney cancer	0.000294	0.0088	CbGeAlD
Imatinib—KIT—gonad—kidney cancer	0.000292	0.00875	CbGeAlD
Imatinib—CA1—kidney—kidney cancer	0.000288	0.00863	CbGeAlD
Imatinib—PDGFRB—gonad—kidney cancer	0.000286	0.00855	CbGeAlD
Imatinib—PDGFRB—cardiac atrium—kidney cancer	0.000285	0.00854	CbGeAlD
Imatinib—ABL1—renal system—kidney cancer	0.000284	0.0085	CbGeAlD
Imatinib—CYP3A4—Doxorubicin—kidney cancer	0.000282	0.000605	CbGbCtD
Imatinib—ABL1—kidney—kidney cancer	0.000274	0.00821	CbGeAlD
Imatinib—SLC22A1—renal system—kidney cancer	0.000274	0.00819	CbGeAlD
Imatinib—ABL1—cortex of kidney—kidney cancer	0.000267	0.008	CbGeAlD
Imatinib—SLC22A1—kidney—kidney cancer	0.000265	0.00792	CbGeAlD
Imatinib—ABL1—gonad—kidney cancer	0.000255	0.00762	CbGeAlD
Imatinib—ABL1—cardiac atrium—kidney cancer	0.000254	0.00761	CbGeAlD
Imatinib—CA2—nephron tubule—kidney cancer	0.000213	0.00636	CbGeAlD
Imatinib—ABCG2—nephron tubule—kidney cancer	0.000197	0.00589	CbGeAlD
Imatinib—CA2—renal system—kidney cancer	0.000193	0.00578	CbGeAlD
Imatinib—CA2—kidney—kidney cancer	0.000187	0.00559	CbGeAlD
Imatinib—CYP3A5—nephron tubule—kidney cancer	0.000183	0.00547	CbGeAlD
Imatinib—CA2—cortex of kidney—kidney cancer	0.000182	0.00545	CbGeAlD
Imatinib—CA2—cardiac atrium—kidney cancer	0.000173	0.00518	CbGeAlD
Imatinib—CYP1A2—renal system—kidney cancer	0.000172	0.00516	CbGeAlD
Imatinib—CYP3A5—renal system—kidney cancer	0.000166	0.00497	CbGeAlD
Imatinib—CYP3A5—kidney—kidney cancer	0.000161	0.00481	CbGeAlD
Imatinib—CYP3A5—cortex of kidney—kidney cancer	0.000156	0.00468	CbGeAlD
Imatinib—PTGS1—renal system—kidney cancer	0.000149	0.00447	CbGeAlD
Imatinib—PTGS1—kidney—kidney cancer	0.000144	0.00432	CbGeAlD
Imatinib—PTGS1—cardiac atrium—kidney cancer	0.000134	0.004	CbGeAlD
Imatinib—CYP3A4—renal system—kidney cancer	0.000125	0.00373	CbGeAlD
Imatinib—CYP2D6—renal system—kidney cancer	0.000123	0.00367	CbGeAlD
Imatinib—CYP3A4—kidney—kidney cancer	0.000121	0.00361	CbGeAlD
Imatinib—CYP2D6—kidney—kidney cancer	0.000119	0.00355	CbGeAlD
Imatinib—Ponatinib—ABCB1—kidney cancer	0.000108	0.0422	CrCbGaD
Imatinib—ABCB1—nephron tubule—kidney cancer	9.71e-05	0.00291	CbGeAlD
Imatinib—ABCB1—renal system—kidney cancer	8.83e-05	0.00264	CbGeAlD
Imatinib—ABCB1—kidney—kidney cancer	8.53e-05	0.00255	CbGeAlD
Imatinib—ABCB1—cortex of kidney—kidney cancer	8.31e-05	0.00249	CbGeAlD
Imatinib—Nilotinib—ABCB1—kidney cancer	7.99e-05	0.0311	CrCbGaD
Imatinib—ABCB1—gonad—kidney cancer	7.92e-05	0.00237	CbGeAlD
Imatinib—Dysgeusia—Capecitabine—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Dizziness—Sunitinib—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Feeling abnormal—Gemcitabine—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Shock—Paclitaxel—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Vomiting—Sorafenib—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Abdominal pain upper—Doxorubicin—kidney cancer	2.09e-05	0.000172	CcSEcCtD
Imatinib—Nervous system disorder—Paclitaxel—kidney cancer	2.08e-05	0.000171	CcSEcCtD
Imatinib—Hypokalaemia—Doxorubicin—kidney cancer	2.08e-05	0.000171	CcSEcCtD
Imatinib—Thrombocytopenia—Paclitaxel—kidney cancer	2.08e-05	0.000171	CcSEcCtD
Imatinib—Tachycardia—Paclitaxel—kidney cancer	2.07e-05	0.000171	CcSEcCtD
Imatinib—Rash—Sorafenib—kidney cancer	2.07e-05	0.00017	CcSEcCtD
Imatinib—Dermatitis—Sorafenib—kidney cancer	2.07e-05	0.00017	CcSEcCtD
Imatinib—Back pain—Capecitabine—kidney cancer	2.06e-05	0.00017	CcSEcCtD
Imatinib—Breast disorder—Doxorubicin—kidney cancer	2.06e-05	0.00017	CcSEcCtD
Imatinib—Skin disorder—Paclitaxel—kidney cancer	2.06e-05	0.00017	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	2.06e-05	0.000169	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	2.06e-05	0.000169	CcSEcCtD
Imatinib—Headache—Sorafenib—kidney cancer	2.06e-05	0.000169	CcSEcCtD
Imatinib—Muscle spasms—Capecitabine—kidney cancer	2.05e-05	0.000169	CcSEcCtD
Imatinib—Hyperhidrosis—Paclitaxel—kidney cancer	2.05e-05	0.000169	CcSEcCtD
Imatinib—Diarrhoea—Dactinomycin—kidney cancer	2.05e-05	0.000168	CcSEcCtD
Imatinib—Nasopharyngitis—Doxorubicin—kidney cancer	2.04e-05	0.000168	CcSEcCtD
Imatinib—Anorexia—Paclitaxel—kidney cancer	2.02e-05	0.000167	CcSEcCtD
Imatinib—Gastritis—Doxorubicin—kidney cancer	2.02e-05	0.000166	CcSEcCtD
Imatinib—Muscular weakness—Doxorubicin—kidney cancer	2.01e-05	0.000166	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.01e-05	0.000166	CcSEcCtD
Imatinib—Vision blurred—Capecitabine—kidney cancer	2.01e-05	0.000166	CcSEcCtD
Imatinib—Vomiting—Sunitinib—kidney cancer	2.01e-05	0.000165	CcSEcCtD
Imatinib—Body temperature increased—Gemcitabine—kidney cancer	2e-05	0.000165	CcSEcCtD
Imatinib—Tremor—Capecitabine—kidney cancer	2e-05	0.000165	CcSEcCtD
Imatinib—Rash—Sunitinib—kidney cancer	1.99e-05	0.000164	CcSEcCtD
Imatinib—Dermatitis—Sunitinib—kidney cancer	1.99e-05	0.000164	CcSEcCtD
Imatinib—Abdominal distension—Doxorubicin—kidney cancer	1.99e-05	0.000164	CcSEcCtD
Imatinib—Hypotension—Paclitaxel—kidney cancer	1.98e-05	0.000163	CcSEcCtD
Imatinib—Ill-defined disorder—Capecitabine—kidney cancer	1.98e-05	0.000163	CcSEcCtD
Imatinib—Headache—Sunitinib—kidney cancer	1.98e-05	0.000163	CcSEcCtD
Imatinib—Dysphagia—Doxorubicin—kidney cancer	1.97e-05	0.000163	CcSEcCtD
Imatinib—Influenza—Doxorubicin—kidney cancer	1.97e-05	0.000163	CcSEcCtD
Imatinib—Anaemia—Capecitabine—kidney cancer	1.97e-05	0.000162	CcSEcCtD
Imatinib—Hypersensitivity—Vincristine—kidney cancer	1.97e-05	0.000162	CcSEcCtD
Imatinib—Eosinophilia—Doxorubicin—kidney cancer	1.95e-05	0.000161	CcSEcCtD
Imatinib—Nausea—Sorafenib—kidney cancer	1.95e-05	0.000161	CcSEcCtD
Imatinib—Pancreatitis—Doxorubicin—kidney cancer	1.93e-05	0.000159	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	1.93e-05	0.000159	CcSEcCtD
Imatinib—Malaise—Capecitabine—kidney cancer	1.92e-05	0.000158	CcSEcCtD
Imatinib—Angina pectoris—Doxorubicin—kidney cancer	1.92e-05	0.000158	CcSEcCtD
Imatinib—Insomnia—Paclitaxel—kidney cancer	1.92e-05	0.000158	CcSEcCtD
Imatinib—Vertigo—Capecitabine—kidney cancer	1.92e-05	0.000158	CcSEcCtD
Imatinib—Asthenia—Vincristine—kidney cancer	1.92e-05	0.000158	CcSEcCtD
Imatinib—Syncope—Capecitabine—kidney cancer	1.91e-05	0.000158	CcSEcCtD
Imatinib—Leukopenia—Capecitabine—kidney cancer	1.91e-05	0.000157	CcSEcCtD
Imatinib—Paraesthesia—Paclitaxel—kidney cancer	1.9e-05	0.000157	CcSEcCtD
Imatinib—Vomiting—Dactinomycin—kidney cancer	1.9e-05	0.000157	CcSEcCtD
Imatinib—Dyspnoea—Paclitaxel—kidney cancer	1.89e-05	0.000156	CcSEcCtD
Imatinib—Somnolence—Paclitaxel—kidney cancer	1.89e-05	0.000155	CcSEcCtD
Imatinib—Palpitations—Capecitabine—kidney cancer	1.89e-05	0.000155	CcSEcCtD
Imatinib—Rash—Dactinomycin—kidney cancer	1.88e-05	0.000155	CcSEcCtD
Imatinib—Nausea—Sunitinib—kidney cancer	1.88e-05	0.000155	CcSEcCtD
Imatinib—Loss of consciousness—Capecitabine—kidney cancer	1.87e-05	0.000154	CcSEcCtD
Imatinib—Pancytopenia—Doxorubicin—kidney cancer	1.87e-05	0.000154	CcSEcCtD
Imatinib—Dyspepsia—Paclitaxel—kidney cancer	1.87e-05	0.000154	CcSEcCtD
Imatinib—Cough—Capecitabine—kidney cancer	1.86e-05	0.000153	CcSEcCtD
Imatinib—Neutropenia—Doxorubicin—kidney cancer	1.85e-05	0.000152	CcSEcCtD
Imatinib—Decreased appetite—Paclitaxel—kidney cancer	1.84e-05	0.000152	CcSEcCtD
Imatinib—Hypertension—Capecitabine—kidney cancer	1.84e-05	0.000152	CcSEcCtD
Imatinib—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.83e-05	0.000151	CcSEcCtD
Imatinib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.83e-05	0.000151	CcSEcCtD
Imatinib—Fatigue—Paclitaxel—kidney cancer	1.83e-05	0.000151	CcSEcCtD
Imatinib—Diarrhoea—Vincristine—kidney cancer	1.83e-05	0.000151	CcSEcCtD
Imatinib—Pollakiuria—Doxorubicin—kidney cancer	1.82e-05	0.00015	CcSEcCtD
Imatinib—Asthenia—Gemcitabine—kidney cancer	1.82e-05	0.00015	CcSEcCtD
Imatinib—Chest pain—Capecitabine—kidney cancer	1.82e-05	0.00015	CcSEcCtD
Imatinib—Arthralgia—Capecitabine—kidney cancer	1.82e-05	0.00015	CcSEcCtD
Imatinib—Myalgia—Capecitabine—kidney cancer	1.82e-05	0.00015	CcSEcCtD
Imatinib—Pain—Paclitaxel—kidney cancer	1.81e-05	0.000149	CcSEcCtD
Imatinib—Constipation—Paclitaxel—kidney cancer	1.81e-05	0.000149	CcSEcCtD
Imatinib—Anxiety—Capecitabine—kidney cancer	1.81e-05	0.000149	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.8e-05	0.000149	CcSEcCtD
Imatinib—Photosensitivity reaction—Doxorubicin—kidney cancer	1.8e-05	0.000148	CcSEcCtD
Imatinib—Weight increased—Doxorubicin—kidney cancer	1.8e-05	0.000148	CcSEcCtD
Imatinib—Discomfort—Capecitabine—kidney cancer	1.79e-05	0.000148	CcSEcCtD
Imatinib—Pruritus—Gemcitabine—kidney cancer	1.79e-05	0.000148	CcSEcCtD
Imatinib—Weight decreased—Doxorubicin—kidney cancer	1.79e-05	0.000147	CcSEcCtD
Imatinib—Hyperglycaemia—Doxorubicin—kidney cancer	1.78e-05	0.000147	CcSEcCtD
Imatinib—Dry mouth—Capecitabine—kidney cancer	1.78e-05	0.000146	CcSEcCtD
Imatinib—Nausea—Dactinomycin—kidney cancer	1.78e-05	0.000146	CcSEcCtD
Imatinib—Pneumonia—Doxorubicin—kidney cancer	1.77e-05	0.000146	CcSEcCtD
Imatinib—Dizziness—Vincristine—kidney cancer	1.77e-05	0.000145	CcSEcCtD
Imatinib—Infestation—Doxorubicin—kidney cancer	1.76e-05	0.000145	CcSEcCtD
Imatinib—Infestation NOS—Doxorubicin—kidney cancer	1.76e-05	0.000145	CcSEcCtD
Imatinib—Confusional state—Capecitabine—kidney cancer	1.76e-05	0.000145	CcSEcCtD
Imatinib—Feeling abnormal—Paclitaxel—kidney cancer	1.75e-05	0.000144	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	1.74e-05	0.000144	CcSEcCtD
Imatinib—Oedema—Capecitabine—kidney cancer	1.74e-05	0.000143	CcSEcCtD
Imatinib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.73e-05	0.000143	CcSEcCtD
Imatinib—Diarrhoea—Gemcitabine—kidney cancer	1.73e-05	0.000143	CcSEcCtD
Imatinib—Renal failure—Doxorubicin—kidney cancer	1.73e-05	0.000142	CcSEcCtD
Imatinib—Infection—Capecitabine—kidney cancer	1.73e-05	0.000142	CcSEcCtD
Imatinib—Neuropathy peripheral—Doxorubicin—kidney cancer	1.72e-05	0.000142	CcSEcCtD
Imatinib—Jaundice—Doxorubicin—kidney cancer	1.72e-05	0.000141	CcSEcCtD
Imatinib—Stomatitis—Doxorubicin—kidney cancer	1.72e-05	0.000141	CcSEcCtD
Imatinib—Shock—Capecitabine—kidney cancer	1.71e-05	0.000141	CcSEcCtD
Imatinib—Urinary tract infection—Doxorubicin—kidney cancer	1.71e-05	0.000141	CcSEcCtD
Imatinib—Conjunctivitis—Doxorubicin—kidney cancer	1.71e-05	0.000141	CcSEcCtD
Imatinib—Nervous system disorder—Capecitabine—kidney cancer	1.71e-05	0.000141	CcSEcCtD
Imatinib—Thrombocytopenia—Capecitabine—kidney cancer	1.7e-05	0.00014	CcSEcCtD
Imatinib—Tachycardia—Capecitabine—kidney cancer	1.7e-05	0.00014	CcSEcCtD
Imatinib—Vomiting—Vincristine—kidney cancer	1.7e-05	0.00014	CcSEcCtD
Imatinib—Skin disorder—Capecitabine—kidney cancer	1.69e-05	0.000139	CcSEcCtD
Imatinib—Sweating—Doxorubicin—kidney cancer	1.69e-05	0.000139	CcSEcCtD
Imatinib—Urticaria—Paclitaxel—kidney cancer	1.69e-05	0.000139	CcSEcCtD
Imatinib—Rash—Vincristine—kidney cancer	1.68e-05	0.000139	CcSEcCtD
Imatinib—Hyperhidrosis—Capecitabine—kidney cancer	1.68e-05	0.000139	CcSEcCtD
Imatinib—Dermatitis—Vincristine—kidney cancer	1.68e-05	0.000139	CcSEcCtD
Imatinib—Haematuria—Doxorubicin—kidney cancer	1.68e-05	0.000138	CcSEcCtD
Imatinib—Abdominal pain—Paclitaxel—kidney cancer	1.68e-05	0.000138	CcSEcCtD
Imatinib—Body temperature increased—Paclitaxel—kidney cancer	1.68e-05	0.000138	CcSEcCtD
Imatinib—Headache—Vincristine—kidney cancer	1.67e-05	0.000138	CcSEcCtD
Imatinib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.66e-05	0.000137	CcSEcCtD
Imatinib—Epistaxis—Doxorubicin—kidney cancer	1.66e-05	0.000137	CcSEcCtD
Imatinib—Anorexia—Capecitabine—kidney cancer	1.66e-05	0.000137	CcSEcCtD
Imatinib—Sinusitis—Doxorubicin—kidney cancer	1.65e-05	0.000136	CcSEcCtD
Imatinib—Agranulocytosis—Doxorubicin—kidney cancer	1.64e-05	0.000135	CcSEcCtD
Imatinib—Hypotension—Capecitabine—kidney cancer	1.63e-05	0.000134	CcSEcCtD
Imatinib—Vomiting—Gemcitabine—kidney cancer	1.61e-05	0.000133	CcSEcCtD
Imatinib—Rash—Gemcitabine—kidney cancer	1.6e-05	0.000132	CcSEcCtD
Imatinib—Dermatitis—Gemcitabine—kidney cancer	1.6e-05	0.000131	CcSEcCtD
Imatinib—Haemoglobin—Doxorubicin—kidney cancer	1.59e-05	0.000131	CcSEcCtD
Imatinib—Headache—Gemcitabine—kidney cancer	1.59e-05	0.000131	CcSEcCtD
Imatinib—Nausea—Vincristine—kidney cancer	1.59e-05	0.000131	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.59e-05	0.000131	CcSEcCtD
Imatinib—Rhinitis—Doxorubicin—kidney cancer	1.58e-05	0.00013	CcSEcCtD
Imatinib—Haemorrhage—Doxorubicin—kidney cancer	1.58e-05	0.00013	CcSEcCtD
Imatinib—Hepatitis—Doxorubicin—kidney cancer	1.58e-05	0.00013	CcSEcCtD
Imatinib—Insomnia—Capecitabine—kidney cancer	1.57e-05	0.00013	CcSEcCtD
Imatinib—Hypoaesthesia—Doxorubicin—kidney cancer	1.57e-05	0.000129	CcSEcCtD
Imatinib—Pharyngitis—Doxorubicin—kidney cancer	1.57e-05	0.000129	CcSEcCtD
Imatinib—Paraesthesia—Capecitabine—kidney cancer	1.56e-05	0.000129	CcSEcCtD
Imatinib—Hypersensitivity—Paclitaxel—kidney cancer	1.56e-05	0.000129	CcSEcCtD
Imatinib—Urinary tract disorder—Doxorubicin—kidney cancer	1.56e-05	0.000128	CcSEcCtD
Imatinib—Oedema peripheral—Doxorubicin—kidney cancer	1.56e-05	0.000128	CcSEcCtD
Imatinib—Connective tissue disorder—Doxorubicin—kidney cancer	1.55e-05	0.000128	CcSEcCtD
Imatinib—Dyspnoea—Capecitabine—kidney cancer	1.55e-05	0.000128	CcSEcCtD
Imatinib—Urethral disorder—Doxorubicin—kidney cancer	1.55e-05	0.000128	CcSEcCtD
Imatinib—Dyspepsia—Capecitabine—kidney cancer	1.53e-05	0.000126	CcSEcCtD
Imatinib—Asthenia—Paclitaxel—kidney cancer	1.52e-05	0.000125	CcSEcCtD
Imatinib—Decreased appetite—Capecitabine—kidney cancer	1.51e-05	0.000125	CcSEcCtD
Imatinib—Nausea—Gemcitabine—kidney cancer	1.51e-05	0.000124	CcSEcCtD
Imatinib—Gastrointestinal disorder—Capecitabine—kidney cancer	1.5e-05	0.000124	CcSEcCtD
Imatinib—Fatigue—Capecitabine—kidney cancer	1.5e-05	0.000124	CcSEcCtD
Imatinib—Pruritus—Paclitaxel—kidney cancer	1.5e-05	0.000124	CcSEcCtD
Imatinib—Erythema multiforme—Doxorubicin—kidney cancer	1.49e-05	0.000123	CcSEcCtD
Imatinib—Pain—Capecitabine—kidney cancer	1.49e-05	0.000123	CcSEcCtD
Imatinib—Constipation—Capecitabine—kidney cancer	1.49e-05	0.000123	CcSEcCtD
Imatinib—Eye disorder—Doxorubicin—kidney cancer	1.48e-05	0.000122	CcSEcCtD
Imatinib—Tinnitus—Doxorubicin—kidney cancer	1.47e-05	0.000121	CcSEcCtD
Imatinib—Flushing—Doxorubicin—kidney cancer	1.47e-05	0.000121	CcSEcCtD
Imatinib—Cardiac disorder—Doxorubicin—kidney cancer	1.47e-05	0.000121	CcSEcCtD
Imatinib—Diarrhoea—Paclitaxel—kidney cancer	1.45e-05	0.00012	CcSEcCtD
Imatinib—Feeling abnormal—Capecitabine—kidney cancer	1.43e-05	0.000118	CcSEcCtD
Imatinib—Angiopathy—Doxorubicin—kidney cancer	1.43e-05	0.000118	CcSEcCtD
Imatinib—Immune system disorder—Doxorubicin—kidney cancer	1.43e-05	0.000118	CcSEcCtD
Imatinib—Gastrointestinal pain—Capecitabine—kidney cancer	1.42e-05	0.000117	CcSEcCtD
Imatinib—Mediastinal disorder—Doxorubicin—kidney cancer	1.42e-05	0.000117	CcSEcCtD
Imatinib—Chills—Doxorubicin—kidney cancer	1.42e-05	0.000117	CcSEcCtD
Imatinib—Arrhythmia—Doxorubicin—kidney cancer	1.41e-05	0.000116	CcSEcCtD
Imatinib—Dizziness—Paclitaxel—kidney cancer	1.4e-05	0.000116	CcSEcCtD
Imatinib—Alopecia—Doxorubicin—kidney cancer	1.4e-05	0.000115	CcSEcCtD
Imatinib—Mental disorder—Doxorubicin—kidney cancer	1.38e-05	0.000114	CcSEcCtD
Imatinib—Urticaria—Capecitabine—kidney cancer	1.38e-05	0.000114	CcSEcCtD
Imatinib—Body temperature increased—Capecitabine—kidney cancer	1.38e-05	0.000113	CcSEcCtD
Imatinib—Abdominal pain—Capecitabine—kidney cancer	1.38e-05	0.000113	CcSEcCtD
Imatinib—Erythema—Doxorubicin—kidney cancer	1.38e-05	0.000113	CcSEcCtD
Imatinib—Malnutrition—Doxorubicin—kidney cancer	1.38e-05	0.000113	CcSEcCtD
Imatinib—Flatulence—Doxorubicin—kidney cancer	1.35e-05	0.000112	CcSEcCtD
Imatinib—Vomiting—Paclitaxel—kidney cancer	1.35e-05	0.000111	CcSEcCtD
Imatinib—Dysgeusia—Doxorubicin—kidney cancer	1.35e-05	0.000111	CcSEcCtD
Imatinib—Rash—Paclitaxel—kidney cancer	1.34e-05	0.00011	CcSEcCtD
Imatinib—Dermatitis—Paclitaxel—kidney cancer	1.34e-05	0.00011	CcSEcCtD
Imatinib—Back pain—Doxorubicin—kidney cancer	1.33e-05	0.00011	CcSEcCtD
Imatinib—Headache—Paclitaxel—kidney cancer	1.33e-05	0.000109	CcSEcCtD
Imatinib—Muscle spasms—Doxorubicin—kidney cancer	1.32e-05	0.000109	CcSEcCtD
Imatinib—Vision blurred—Doxorubicin—kidney cancer	1.3e-05	0.000107	CcSEcCtD
Imatinib—Hypersensitivity—Capecitabine—kidney cancer	1.28e-05	0.000106	CcSEcCtD
Imatinib—Ill-defined disorder—Doxorubicin—kidney cancer	1.28e-05	0.000105	CcSEcCtD
Imatinib—Anaemia—Doxorubicin—kidney cancer	1.27e-05	0.000105	CcSEcCtD
Imatinib—Nausea—Paclitaxel—kidney cancer	1.26e-05	0.000104	CcSEcCtD
Imatinib—Asthenia—Capecitabine—kidney cancer	1.25e-05	0.000103	CcSEcCtD
Imatinib—Malaise—Doxorubicin—kidney cancer	1.24e-05	0.000102	CcSEcCtD
Imatinib—Vertigo—Doxorubicin—kidney cancer	1.24e-05	0.000102	CcSEcCtD
Imatinib—Syncope—Doxorubicin—kidney cancer	1.23e-05	0.000102	CcSEcCtD
Imatinib—Pruritus—Capecitabine—kidney cancer	1.23e-05	0.000101	CcSEcCtD
Imatinib—Leukopenia—Doxorubicin—kidney cancer	1.23e-05	0.000101	CcSEcCtD
Imatinib—Palpitations—Doxorubicin—kidney cancer	1.22e-05	0.0001	CcSEcCtD
Imatinib—Loss of consciousness—Doxorubicin—kidney cancer	1.21e-05	9.96e-05	CcSEcCtD
Imatinib—Cough—Doxorubicin—kidney cancer	1.2e-05	9.88e-05	CcSEcCtD
Imatinib—Convulsion—Doxorubicin—kidney cancer	1.19e-05	9.81e-05	CcSEcCtD
Imatinib—Diarrhoea—Capecitabine—kidney cancer	1.19e-05	9.81e-05	CcSEcCtD
Imatinib—Hypertension—Doxorubicin—kidney cancer	1.19e-05	9.78e-05	CcSEcCtD
Imatinib—Arthralgia—Doxorubicin—kidney cancer	1.17e-05	9.64e-05	CcSEcCtD
Imatinib—Chest pain—Doxorubicin—kidney cancer	1.17e-05	9.64e-05	CcSEcCtD
Imatinib—Myalgia—Doxorubicin—kidney cancer	1.17e-05	9.64e-05	CcSEcCtD
Imatinib—Anxiety—Doxorubicin—kidney cancer	1.17e-05	9.61e-05	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.16e-05	9.58e-05	CcSEcCtD
Imatinib—Discomfort—Doxorubicin—kidney cancer	1.16e-05	9.53e-05	CcSEcCtD
Imatinib—Dizziness—Capecitabine—kidney cancer	1.15e-05	9.48e-05	CcSEcCtD
Imatinib—Dry mouth—Doxorubicin—kidney cancer	1.14e-05	9.43e-05	CcSEcCtD
Imatinib—Confusional state—Doxorubicin—kidney cancer	1.13e-05	9.32e-05	CcSEcCtD
Imatinib—Oedema—Doxorubicin—kidney cancer	1.12e-05	9.24e-05	CcSEcCtD
Imatinib—Anaphylactic shock—Doxorubicin—kidney cancer	1.12e-05	9.24e-05	CcSEcCtD
Imatinib—Infection—Doxorubicin—kidney cancer	1.11e-05	9.18e-05	CcSEcCtD
Imatinib—Vomiting—Capecitabine—kidney cancer	1.11e-05	9.12e-05	CcSEcCtD
Imatinib—Shock—Doxorubicin—kidney cancer	1.1e-05	9.09e-05	CcSEcCtD
Imatinib—Nervous system disorder—Doxorubicin—kidney cancer	1.1e-05	9.07e-05	CcSEcCtD
Imatinib—Thrombocytopenia—Doxorubicin—kidney cancer	1.1e-05	9.05e-05	CcSEcCtD
Imatinib—Rash—Capecitabine—kidney cancer	1.1e-05	9.04e-05	CcSEcCtD
Imatinib—Dermatitis—Capecitabine—kidney cancer	1.1e-05	9.03e-05	CcSEcCtD
Imatinib—Tachycardia—Doxorubicin—kidney cancer	1.1e-05	9.02e-05	CcSEcCtD
Imatinib—Headache—Capecitabine—kidney cancer	1.09e-05	8.98e-05	CcSEcCtD
Imatinib—Skin disorder—Doxorubicin—kidney cancer	1.09e-05	8.98e-05	CcSEcCtD
Imatinib—Hyperhidrosis—Doxorubicin—kidney cancer	1.08e-05	8.94e-05	CcSEcCtD
Imatinib—Anorexia—Doxorubicin—kidney cancer	1.07e-05	8.81e-05	CcSEcCtD
Imatinib—Hypotension—Doxorubicin—kidney cancer	1.05e-05	8.64e-05	CcSEcCtD
Imatinib—Nausea—Capecitabine—kidney cancer	1.03e-05	8.52e-05	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.02e-05	8.42e-05	CcSEcCtD
Imatinib—Insomnia—Doxorubicin—kidney cancer	1.01e-05	8.36e-05	CcSEcCtD
Imatinib—Paraesthesia—Doxorubicin—kidney cancer	1.01e-05	8.3e-05	CcSEcCtD
Imatinib—Dyspnoea—Doxorubicin—kidney cancer	1e-05	8.24e-05	CcSEcCtD
Imatinib—Somnolence—Doxorubicin—kidney cancer	9.98e-06	8.22e-05	CcSEcCtD
Imatinib—Dyspepsia—Doxorubicin—kidney cancer	9.88e-06	8.14e-05	CcSEcCtD
Imatinib—Decreased appetite—Doxorubicin—kidney cancer	9.76e-06	8.04e-05	CcSEcCtD
Imatinib—Gastrointestinal disorder—Doxorubicin—kidney cancer	9.69e-06	7.98e-05	CcSEcCtD
Imatinib—Fatigue—Doxorubicin—kidney cancer	9.68e-06	7.97e-05	CcSEcCtD
Imatinib—Constipation—Doxorubicin—kidney cancer	9.6e-06	7.91e-05	CcSEcCtD
Imatinib—Pain—Doxorubicin—kidney cancer	9.6e-06	7.91e-05	CcSEcCtD
Imatinib—Feeling abnormal—Doxorubicin—kidney cancer	9.25e-06	7.62e-05	CcSEcCtD
Imatinib—Gastrointestinal pain—Doxorubicin—kidney cancer	9.18e-06	7.56e-05	CcSEcCtD
Imatinib—Urticaria—Doxorubicin—kidney cancer	8.92e-06	7.34e-05	CcSEcCtD
Imatinib—Body temperature increased—Doxorubicin—kidney cancer	8.87e-06	7.31e-05	CcSEcCtD
Imatinib—Abdominal pain—Doxorubicin—kidney cancer	8.87e-06	7.31e-05	CcSEcCtD
Imatinib—Hypersensitivity—Doxorubicin—kidney cancer	8.27e-06	6.81e-05	CcSEcCtD
Imatinib—Asthenia—Doxorubicin—kidney cancer	8.05e-06	6.63e-05	CcSEcCtD
Imatinib—Pruritus—Doxorubicin—kidney cancer	7.94e-06	6.54e-05	CcSEcCtD
Imatinib—Diarrhoea—Doxorubicin—kidney cancer	7.68e-06	6.33e-05	CcSEcCtD
Imatinib—Dizziness—Doxorubicin—kidney cancer	7.42e-06	6.11e-05	CcSEcCtD
Imatinib—Vomiting—Doxorubicin—kidney cancer	7.14e-06	5.88e-05	CcSEcCtD
Imatinib—Rash—Doxorubicin—kidney cancer	7.08e-06	5.83e-05	CcSEcCtD
Imatinib—Dermatitis—Doxorubicin—kidney cancer	7.07e-06	5.82e-05	CcSEcCtD
Imatinib—Headache—Doxorubicin—kidney cancer	7.03e-06	5.79e-05	CcSEcCtD
Imatinib—Nausea—Doxorubicin—kidney cancer	6.67e-06	5.49e-05	CcSEcCtD
Imatinib—CYP3A4—Metabolism—CA9—kidney cancer	1.43e-06	2e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAPK3—kidney cancer	1.42e-06	2e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SLC2A1—kidney cancer	1.42e-06	1.99e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MAPK1—kidney cancer	1.41e-06	1.99e-05	CbGpPWpGaD
Imatinib—LCK—Disease—RAF1—kidney cancer	1.41e-06	1.98e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MTOR—kidney cancer	1.41e-06	1.98e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTM1—kidney cancer	1.41e-06	1.98e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAPK3—kidney cancer	1.41e-06	1.98e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CDKN1B—kidney cancer	1.4e-06	1.97e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ERBB2—kidney cancer	1.4e-06	1.96e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—POMC—kidney cancer	1.39e-06	1.95e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SLC2A1—kidney cancer	1.39e-06	1.95e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—kidney cancer	1.38e-06	1.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MTOR—kidney cancer	1.38e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.38e-06	1.93e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—POMC—kidney cancer	1.38e-06	1.93e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—kidney cancer	1.38e-06	1.93e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—POMC—kidney cancer	1.37e-06	1.93e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MAPK3—kidney cancer	1.37e-06	1.93e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KRAS—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—BCHE—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RAF1—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KDR—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—kidney cancer	1.37e-06	1.92e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—RELA—kidney cancer	1.36e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—BCHE—kidney cancer	1.36e-06	1.91e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ERBB2—kidney cancer	1.35e-06	1.9e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.35e-06	1.9e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAPK1—kidney cancer	1.35e-06	1.9e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—PIK3CA—kidney cancer	1.35e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.35e-06	1.89e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.34e-06	1.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAPK1—kidney cancer	1.34e-06	1.88e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.34e-06	1.88e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MAPK3—kidney cancer	1.34e-06	1.88e-05	CbGpPWpGaD
Imatinib—KIT—Disease—KRAS—kidney cancer	1.34e-06	1.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MTOR—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP1A1—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—POMC—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—JUN—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTT1—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ACHE—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—PIK3CA—kidney cancer	1.33e-06	1.87e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—kidney cancer	1.33e-06	1.86e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CDKN1B—kidney cancer	1.32e-06	1.86e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—CTNNB1—kidney cancer	1.32e-06	1.86e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.32e-06	1.86e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTP1—kidney cancer	1.32e-06	1.85e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MAPK1—kidney cancer	1.31e-06	1.83e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.31e-06	1.83e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—kidney cancer	1.29e-06	1.82e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.29e-06	1.82e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CDKN1B—kidney cancer	1.29e-06	1.82e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PTEN—kidney cancer	1.29e-06	1.81e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—POMC—kidney cancer	1.28e-06	1.8e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KRAS—kidney cancer	1.28e-06	1.79e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MAPK1—kidney cancer	1.27e-06	1.79e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK3—kidney cancer	1.27e-06	1.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KRAS—kidney cancer	1.26e-06	1.78e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SCARB1—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—JUN—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—APC—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIT—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—PIK3CA—kidney cancer	1.26e-06	1.77e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.26e-06	1.76e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK3—kidney cancer	1.26e-06	1.76e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CDKN1B—kidney cancer	1.25e-06	1.76e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CTNNB1—kidney cancer	1.25e-06	1.76e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ABCB1—kidney cancer	1.25e-06	1.75e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS1—kidney cancer	1.25e-06	1.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KRAS—kidney cancer	1.23e-06	1.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—kidney cancer	1.23e-06	1.73e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	1.23e-06	1.73e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—kidney cancer	1.23e-06	1.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—RELA—kidney cancer	1.23e-06	1.72e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—kidney cancer	1.23e-06	1.72e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PSMD7—kidney cancer	1.22e-06	1.72e-05	CbGpPWpGaD
Imatinib—LCK—Disease—CTNNB1—kidney cancer	1.22e-06	1.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	1.22e-06	1.71e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—kidney cancer	1.22e-06	1.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—kidney cancer	1.21e-06	1.7e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CRABP1—kidney cancer	1.21e-06	1.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK1—kidney cancer	1.21e-06	1.69e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—KRAS—kidney cancer	1.2e-06	1.69e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	1.2e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.2e-06	1.69e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—POMC—kidney cancer	1.2e-06	1.68e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK1—kidney cancer	1.2e-06	1.68e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	1.19e-06	1.68e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—JUN—kidney cancer	1.19e-06	1.67e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—kidney cancer	1.19e-06	1.67e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTP1—kidney cancer	1.18e-06	1.66e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—BRAF—kidney cancer	1.18e-06	1.66e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	1.18e-06	1.66e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—kidney cancer	1.17e-06	1.65e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—kidney cancer	1.16e-06	1.63e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—BCHE—kidney cancer	1.16e-06	1.63e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTP1—kidney cancer	1.16e-06	1.62e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	1.15e-06	1.62e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A1—kidney cancer	1.15e-06	1.61e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.15e-06	1.61e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KRAS—kidney cancer	1.14e-06	1.6e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—kidney cancer	1.13e-06	1.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—kidney cancer	1.13e-06	1.59e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—KRAS—kidney cancer	1.13e-06	1.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	1.13e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ITPR2—kidney cancer	1.13e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ABCB1—kidney cancer	1.12e-06	1.57e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—kidney cancer	1.11e-06	1.56e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.11e-06	1.55e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—kidney cancer	1.1e-06	1.55e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—kidney cancer	1.1e-06	1.55e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK3—kidney cancer	1.1e-06	1.55e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—kidney cancer	1.1e-06	1.55e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—kidney cancer	1.1e-06	1.54e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—kidney cancer	1.1e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.1e-06	1.54e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTP1—kidney cancer	1.09e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—kidney cancer	1.09e-06	1.53e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTP1—kidney cancer	1.08e-06	1.52e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	1.08e-06	1.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—JUN—kidney cancer	1.07e-06	1.51e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.07e-06	1.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	1.07e-06	1.5e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—kidney cancer	1.06e-06	1.49e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—kidney cancer	1.06e-06	1.49e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK1—kidney cancer	1.05e-06	1.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—kidney cancer	1.05e-06	1.47e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	1.04e-06	1.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—kidney cancer	1.04e-06	1.46e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	1.04e-06	1.46e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—kidney cancer	1.04e-06	1.46e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A1—kidney cancer	1.03e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ABCB1—kidney cancer	1.03e-06	1.45e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTT1—kidney cancer	1.03e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ACHE—kidney cancer	1.03e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ABCB1—kidney cancer	1.02e-06	1.44e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—kidney cancer	1.02e-06	1.43e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—kidney cancer	1.02e-06	1.43e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—kidney cancer	1.01e-06	1.42e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—kidney cancer	1.01e-06	1.41e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—kidney cancer	1e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—kidney cancer	1e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—POMC—kidney cancer	9.95e-07	1.4e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—kidney cancer	9.92e-07	1.39e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK1—kidney cancer	9.9e-07	1.39e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—KRAS—kidney cancer	9.9e-07	1.39e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—kidney cancer	9.89e-07	1.39e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RAF1—kidney cancer	9.88e-07	1.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	9.85e-07	1.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—RELA—kidney cancer	9.84e-07	1.38e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ERBB2—kidney cancer	9.78e-07	1.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SCARB1—kidney cancer	9.72e-07	1.37e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK1—kidney cancer	9.68e-07	1.36e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—kidney cancer	9.66e-07	1.36e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MTOR—kidney cancer	9.65e-07	1.36e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS1—kidney cancer	9.63e-07	1.35e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—kidney cancer	9.58e-07	1.35e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—kidney cancer	9.57e-07	1.34e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—kidney cancer	9.56e-07	1.34e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—kidney cancer	9.49e-07	1.33e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.44e-07	1.33e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMD7—kidney cancer	9.44e-07	1.33e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—kidney cancer	9.41e-07	1.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	9.38e-07	1.32e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	9.37e-07	1.32e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	9.36e-07	1.31e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—KRAS—kidney cancer	9.35e-07	1.31e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—kidney cancer	9.28e-07	1.3e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTP1—kidney cancer	9.23e-07	1.3e-05	CbGpPWpGaD
Imatinib—LCK—Disease—KRAS—kidney cancer	9.14e-07	1.28e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—kidney cancer	9.1e-07	1.28e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CDKN1B—kidney cancer	9.05e-07	1.27e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—BCHE—kidney cancer	8.95e-07	1.26e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—kidney cancer	8.91e-07	1.25e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	8.88e-07	1.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—kidney cancer	8.86e-07	1.24e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	8.85e-07	1.24e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC5A5—kidney cancer	8.84e-07	1.24e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ABCB1—kidney cancer	8.73e-07	1.23e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—kidney cancer	8.64e-07	1.21e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—kidney cancer	8.63e-07	1.21e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—JUN—kidney cancer	8.62e-07	1.21e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—kidney cancer	8.59e-07	1.21e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—POMC—kidney cancer	8.57e-07	1.2e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CTNNB1—kidney cancer	8.55e-07	1.2e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A1—kidney cancer	8.54e-07	1.2e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—kidney cancer	8.48e-07	1.19e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.47e-07	1.19e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	8.45e-07	1.19e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—kidney cancer	8.4e-07	1.18e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—kidney cancer	8.34e-07	1.17e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—kidney cancer	8.31e-07	1.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	8.13e-07	1.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—kidney cancer	8.04e-07	1.13e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	7.98e-07	1.12e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—kidney cancer	7.93e-07	1.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—kidney cancer	7.87e-07	1.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	7.73e-07	1.09e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—POMC—kidney cancer	7.69e-07	1.08e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—kidney cancer	7.53e-07	1.06e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—POMC—kidney cancer	7.51e-07	1.05e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	7.33e-07	1.03e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—kidney cancer	7.12e-07	1e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTP1—kidney cancer	7.12e-07	1e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—kidney cancer	7.09e-07	9.96e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—POMC—kidney cancer	7.07e-07	9.94e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—POMC—kidney cancer	7.01e-07	9.85e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—kidney cancer	6.93e-07	9.73e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—kidney cancer	6.92e-07	9.72e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—kidney cancer	6.83e-07	9.6e-06	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—kidney cancer	6.81e-07	9.57e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK1—kidney cancer	6.78e-07	9.52e-06	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—kidney cancer	6.75e-07	9.49e-06	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—kidney cancer	6.74e-07	9.47e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ABCB1—kidney cancer	6.74e-07	9.47e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	6.6e-07	9.27e-06	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—kidney cancer	6.55e-07	9.19e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—kidney cancer	6.54e-07	9.19e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KRAS—kidney cancer	6.4e-07	8.99e-06	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—kidney cancer	6.29e-07	8.83e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—kidney cancer	6.2e-07	8.71e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—kidney cancer	6.13e-07	8.62e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—POMC—kidney cancer	5.99e-07	8.42e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—kidney cancer	5.99e-07	8.41e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—kidney cancer	5.96e-07	8.37e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—kidney cancer	5.88e-07	8.26e-06	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—kidney cancer	5.69e-07	7.99e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—kidney cancer	5.64e-07	7.92e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—kidney cancer	5.59e-07	7.86e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—kidney cancer	5.35e-07	7.51e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—kidney cancer	5.22e-07	7.33e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—kidney cancer	4.92e-07	6.91e-06	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—kidney cancer	4.88e-07	6.86e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—kidney cancer	4.88e-07	6.85e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—kidney cancer	4.78e-07	6.71e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POMC—kidney cancer	4.63e-07	6.5e-06	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—kidney cancer	4.2e-07	5.91e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—kidney cancer	4.17e-07	5.85e-06	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—kidney cancer	3.77e-07	5.3e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—kidney cancer	3.69e-07	5.18e-06	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—kidney cancer	3.68e-07	5.17e-06	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—kidney cancer	3.47e-07	4.88e-06	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—kidney cancer	3.44e-07	4.83e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—kidney cancer	3.22e-07	4.52e-06	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—kidney cancer	2.94e-07	4.13e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.27e-07	3.19e-06	CbGpPWpGaD
